doi: 10.1038/s12276-023-01028-7 44 MorrisGBerkMGaleckiPWalderKMaesM
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
Concept for a unidirectional release mucoadhesive buccal tablet for oral delivery of antidiabetic peptide drugs such as insulin, glucagon-like peptide 1 (GLP-1), and their analogs
A brand that markets unrealistic timelines is more likely to cut corners elsewhere too, such as under-disclosing dosage or using unstandardized ingredient sources
Clean the skin with alcohol
The proper storage of injectable medications is a critical aspect often overlooked, yet it directly impacts the medications stability, potency, and ultimately, its ability to support your health goals